All terms in DRUGBANK

Label Id Description
Polygala senega root DB14749
Morinamide DB13417
Moxestrol DB13418
Polygala tenuifolia root DB14748
Lofepramine DB13411
Avenanthramides DB14743
Pirisudanol DB13412
Olea europaea leaf DB14745
Phenglutarimide DB13413
Fenyramidol DB13414
Spirulina platensis DB14744
Luteinizing hormone DB14741
Guanoxabenz DB13410
Hyaluronidase DB14740
Enfuvirtide DB00109 [Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.]
Glutethimide DB01437 [Glutethimide is a hypnotic and sedative. Its use has been largely superseded by other drugs.]
Abarelix DB00106 [Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.]
Interferon alfa-2b DB00105 [Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.]
Alfacalcidol DB01436 [Alfacalcidol is an active metabolite of Vitamin D, which performs important functions in regulation of the calcium balance and the bone metabolism. Alfacalcidol is Vitamin D-hormone analog which is activated by the enzyme 25-hydroxylase in the liver for systemic and in osteoblasts for local D-hormone actions. It possesses a unique pattern of pleiotropic effects on, e.g. gut, bone, pararthyroids, muscle and brain. Alfacalcidol is superior to plain vitamin D (cholecalciferol) because the final kidney activation of the latter is regulated by a negative feedback mechanism. [A175348,A175351]]
Natalizumab DB00108 [Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006.]